Surrozen, Inc.
SRZNHealthcare|Biotechnology|US
$31.00
+2.00 (+6.90%)
DCF Value
$11.35
Cash / Share
$8.75
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07817121 A First-in-human Trial of SZN-8141 in Diabetic Macular Edema | Diabetic Macular Edema (DME) | P1 | Not Yet Recruiting | 9 | Single-blind | SZN-8141 for Injection |